Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2012

View Archived Issues

Astrocyte-based therapy proven effective in Alzheimer's disease model

Daiichi Sankyo patents new tyrosine-protein kinase inhibitors

Janssen Pharmaceutica divulges new MMP inhibitors

Spanish researchers disclose new GSK-3 beta inhibitors

Soligenix regains North American and European rights to oral BDP

Data presented from a randomized trial comparing rehydration methods in children

BP-2-047 shows antitumor activity against STAT3-activated myeloma in vitro

Baxter presents clinical results for its rFIX protein as hemophilia B treatment

Targeted methods of protein gene therapy for the treatment of brain injury

Janus Biotherapeutics presents novel TLR9 antagonists

Xoma Corp. patents new monoclonal antibodies

Scientists at Lacer divulge novel agents for pain

Novel protein kinase inhibitors prepared at Bayer Intellectual Property

New conjugate presented for metabolic syndrome

Omeros reports results from pivotal phase III trial of OMS-103HP in surgical patients

Johns Hopkins receives additional NIH grant for studies of Q-Cells in ALS

Biotie's nepicastat fails to show efficacy in relieving PTSD symptoms

SBI Holdings reorganizes consolidated subsidiaries to improve efficiency

Japanese group enters agreement for new anticancer compounds

CytImmune and AstraZeneca to study new cancer nanomedicine

FDA accepts supplemental BLA filing for Xiaflex

Kissei submits application in Japan for combination therapy including Glufast

FDA approves Eliquis

Significant reduction in plasma antithrombin demonstrated in nonhuman primates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.